Learn about Saroglitazar , a medication used for managing dyslipidemia in patients with type 2 diabetes. Explore its indications, dosage, contraindications, precautions, and potential side effects. Stay informed about drug interactions for safe and effective use. Saroglitazar is a dual action PPAR inhibitor that lowers cholesterol and blood sugar levels in people with diabetes and fatty liver disease. Learn more about its mechanism, common side effects, available medicines and expert advice on 1mg.com. Saroglitazar helps reduce triglyceride levels considerably, total cholesterol, LDL (bad cholesterol), VLDL, and non-HDL-C. It is especially useful in diabetic and atherogenic dyslipidemia. Reduces HbA1c and fasting plasma glucose in type 2 diabetes. Useful in patients who require simultaneous management of glucose and cholesterol levels. Potentially beneficial in lowering hepatic steatosis and fibrosis. Improving cholesterol and glucose levels may minimize overall cardiovascular risk in ... SAROGLITAZAR : FIRST GLITAZAR TO GAIN REGULATORY NOD Saroglitazar is a novel glitazar compound developed indigenously in India and gained regulatory approval from the Indian regulatory authority DCGI in June 2013.18 It was developed by Zydus Cadilla and is available under the trade name LipaglynTM.
